Abstract: The invention generally features compositions and methods based on the structure-based design of alpha 1-3 N-Acetylgalactosaminyltransferase (alpha 3 GalNAc-T) enzymes from alpha 1-3galactosyltransferase (a3Gal-T) that can transfer 2?-modified galactose from the corresponding UDP-derivatives due to substitutions that broaden the alpha 3Gal-T donor specificity and make the enzyme a3 GalNAc-T.
Type:
Application
Filed:
April 11, 2013
Publication date:
September 19, 2013
Applicant:
Government of the United Sates of America, as represented by the Secretary Department of Health
Inventors:
Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman, Marta Pasek
Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
Type:
Application
Filed:
August 1, 2011
Publication date:
March 15, 2012
Applicants:
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United Sates of America, as represented by the Secretary, Department of Health
Inventors:
Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder